• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

NKT细胞免疫疗法的现状与未来挑战

The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead.

作者信息

Nelson Adam, Lukacs Jordan D, Johnston Brent

机构信息

Department of Microbiology and Immunology, Dalhousie University, Halifax, NS B3H 4R2, Canada.

Beatrice Hunter Cancer Research Institute, Halifax, NS B3H 4R2, Canada.

出版信息

Cancers (Basel). 2021 Oct 15;13(20):5174. doi: 10.3390/cancers13205174.

DOI:10.3390/cancers13205174
PMID:34680322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8533824/
Abstract

NKT cells are a specialized subset of lipid-reactive T lymphocytes that play direct and indirect roles in immunosurveillance and anti-tumor immunity. Preclinical studies have shown that NKT cell activation via delivery of exogenous glycolipids elicits a significant anti-tumor immune response. Furthermore, infiltration of NKT cells is associated with a good prognosis in several cancers. In this review, we aim to summarize the role of NKT cells in cancer as well as the current strategies and status of NKT cell immunotherapy. This review also examines challenges and future directions for improving the therapy.

摘要

NKT细胞是脂质反应性T淋巴细胞的一个特殊亚群,在免疫监视和抗肿瘤免疫中发挥直接和间接作用。临床前研究表明,通过递送外源性糖脂激活NKT细胞可引发显著的抗肿瘤免疫反应。此外,NKT细胞浸润与多种癌症的良好预后相关。在这篇综述中,我们旨在总结NKT细胞在癌症中的作用以及NKT细胞免疫疗法的当前策略和现状。本综述还探讨了改善该疗法的挑战和未来方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c059/8533824/82eede4de211/cancers-13-05174-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c059/8533824/f2fb87608054/cancers-13-05174-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c059/8533824/82eede4de211/cancers-13-05174-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c059/8533824/f2fb87608054/cancers-13-05174-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c059/8533824/82eede4de211/cancers-13-05174-g002.jpg

相似文献

1
The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead.NKT细胞免疫疗法的现状与未来挑战
Cancers (Basel). 2021 Oct 15;13(20):5174. doi: 10.3390/cancers13205174.
2
Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.利用不变自然杀伤 T 细胞进行癌症免疫治疗的新方法。
Front Immunol. 2018 Mar 2;9:384. doi: 10.3389/fimmu.2018.00384. eCollection 2018.
3
Roles of NKT cells in cancer immunotherapy.NKT 细胞在癌症免疫治疗中的作用。
Arch Pharm Res. 2019 Jul;42(7):543-548. doi: 10.1007/s12272-019-01139-8. Epub 2019 Mar 11.
4
Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.用于免疫反应极化的NKT刺激糖脂的定制设计。
J Biomed Sci. 2017 Mar 23;24(1):22. doi: 10.1186/s12929-017-0325-0.
5
NKT cells - New players in CAR cell immunotherapy?NKT 细胞——CAR 细胞免疫疗法的新玩家?
Eur J Haematol. 2018 Dec;101(6):750-757. doi: 10.1111/ejh.13170. Epub 2018 Oct 9.
6
Application of natural killer T cells in antitumor immunotherapy.自然杀伤T细胞在抗肿瘤免疫治疗中的应用。
Crit Rev Immunol. 2007;27(6):511-25. doi: 10.1615/critrevimmunol.v27.i6.20.
7
The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach.自然杀伤 T 细胞在癌症中的作用——表型和功能方法。
Front Immunol. 2018 Feb 27;9:367. doi: 10.3389/fimmu.2018.00367. eCollection 2018.
8
Tissue-Specific Roles of NKT Cells in Tumor Immunity.NKT 细胞在肿瘤免疫中的组织特异性作用。
Front Immunol. 2018 Aug 15;9:1838. doi: 10.3389/fimmu.2018.01838. eCollection 2018.
9
α-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3.α-半乳糖神经酰胺而非苯丙氨酸糖脂通过上调 egr2/3 诱导 NKT 细胞失能和 IL-33 介导的髓系来源抑制细胞积累。
J Immunol. 2014 Feb 15;192(4):1972-81. doi: 10.4049/jimmunol.1302623. Epub 2014 Jan 24.
10
Immunotherapeutic strategies targeting natural killer T cell responses in cancer.针对癌症中自然杀伤T细胞反应的免疫治疗策略。
Immunogenetics. 2016 Aug;68(8):623-38. doi: 10.1007/s00251-016-0928-8. Epub 2016 Jul 8.

引用本文的文献

1
High metabolic activity in positron emission tomography and systemic inflammation occurring years after exposure cessation in engineered stone silicosis.在工程石矽肺中,暴露停止数年之后,正电子发射断层扫描显示出高代谢活性以及全身性炎症。
Sci Rep. 2025 Jul 14;15(1):25364. doi: 10.1038/s41598-025-10562-5.
2
Primordial Cells Bridging the Gap Between Innate and Adaptive Immunity.原始细胞弥合先天免疫与适应性免疫之间的差距。
Adv Exp Med Biol. 2025;1476:47-82. doi: 10.1007/978-3-031-85340-1_3.
3
Integrated analysis of shared gene expression signatures and immune microenvironment heterogeneity in type 2 diabetes mellitus and colorectal cancer.

本文引用的文献

1
Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.肿瘤浸润淋巴细胞亚群在乳腺癌中的预后和治疗作用。
Cancer Metastasis Rev. 2021 Jun;40(2):519-536. doi: 10.1007/s10555-021-09968-0. Epub 2021 May 7.
2
Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.解析胰腺导管腺癌免疫微环境中各成分和特征的预后意义。
Front Immunol. 2021 Mar 10;12:648917. doi: 10.3389/fimmu.2021.648917. eCollection 2021.
3
Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
2型糖尿病与结直肠癌中共享基因表达特征及免疫微环境异质性的综合分析
Sci Rep. 2025 Jul 1;15(1):22234. doi: 10.1038/s41598-025-07015-4.
4
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects.下一代免疫疗法设计与工具的见解:分子机制与治疗前景。
J Hematol Oncol. 2025 Jun 7;18(1):62. doi: 10.1186/s13045-025-01701-6.
5
Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy.破坏γδT细胞激活受体与抑制受体之间的平衡以实现有效的癌症免疫治疗。
Nat Rev Cancer. 2025 Jun 2. doi: 10.1038/s41568-025-00830-x.
6
Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer.解决癌症异基因细胞免疫治疗中的移植物抗宿主病问题。
Exp Hematol Oncol. 2025 May 2;14(1):66. doi: 10.1186/s40164-025-00654-3.
7
Comprehensive immunophenotyping reveals distinct tumor microenvironment alterations in anti-PD-1 sensitive and resistant syngeneic mouse model.全面免疫表型分析揭示了抗PD-1敏感和耐药同基因小鼠模型中不同的肿瘤微环境改变。
Sci Rep. 2025 Mar 10;15(1):8311. doi: 10.1038/s41598-025-91979-w.
8
Prognosis and immune infiltration prediction in neuroblastoma based on neutrophil extracellular traps-related gene signature.基于中性粒细胞胞外诱捕网相关基因特征的神经母细胞瘤预后及免疫浸润预测
Sci Rep. 2025 Feb 13;15(1):5343. doi: 10.1038/s41598-025-88608-x.
9
Patient-Derived Organoid Models for NKT Cell-Based Cancer Immunotherapy.用于基于NKT细胞的癌症免疫疗法的患者来源类器官模型
Cancers (Basel). 2025 Jan 26;17(3):406. doi: 10.3390/cancers17030406.
10
Promising Cellular Immunotherapy for Colorectal Cancer Using Classical Dendritic Cells and Natural Killer T Cells.使用经典树突状细胞和自然杀伤T细胞对结直肠癌进行有前景的细胞免疫治疗。
Cells. 2025 Jan 22;14(3):166. doi: 10.3390/cells14030166.
自然杀伤 T 细胞免疫疗法联合溶瘤单纯疱疹病毒或呼肠孤病毒治疗可显著提高卵巢癌和乳腺癌转移小鼠模型的存活率。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002096.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8 T Cell Responses via CD169 Macrophages and cDC1.含有α-半乳糖神经酰胺和神经节苷脂GM3的脂质体纳米疫苗通过CD169巨噬细胞和cDC1刺激强烈的CD8 T细胞反应。
Vaccines (Basel). 2021 Jan 16;9(1):56. doi: 10.3390/vaccines9010056.
6
Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art.新辅助免疫检查点抑制剂在癌症中的应用:当前的最新进展。
Crit Rev Oncol Hematol. 2021 Jan;157:103172. doi: 10.1016/j.critrevonc.2020.103172. Epub 2020 Nov 12.
7
Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy.先天和类先天细胞:嵌合抗原受体 (CAR) 细胞治疗的未来。
Trends Pharmacol Sci. 2021 Jan;42(1):45-59. doi: 10.1016/j.tips.2020.11.004. Epub 2020 Nov 26.
8
Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer.天然杀伤 T 细胞激动剂 α-半乳糖神经酰胺与 PD-1 阻断协同作用可减少结肠癌临床前模型中的肿瘤发生。
Front Immunol. 2020 Oct 20;11:581301. doi: 10.3389/fimmu.2020.581301. eCollection 2020.
9
First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress.非小细胞肺癌的一线免疫检查点抑制剂:现状与未来进展
Front Pharmacol. 2020 Oct 7;11:578091. doi: 10.3389/fphar.2020.578091. eCollection 2020.
10
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.抗 GD2 CAR-NKT 细胞治疗复发或难治性神经母细胞瘤的初步临床研究
Nat Med. 2020 Nov;26(11):1686-1690. doi: 10.1038/s41591-020-1074-2. Epub 2020 Oct 12.